Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CANCER RES TECH LTD
- Publication Date
- 2019-07-30
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] introduction
[0002] The present invention relates to novel compounds that act as inhibitors of heat shock factor 1 (HSF1) activity. The invention also relates to processes for the preparation of the compounds defined herein, pharmaceutical compositions comprising them, and their use in the treatment of HSF1 -mediated conditions or diseases such as cancer, autoimmune and viral diseases.
[0003] Background of the invention
[0004] Cancer arises from uncontrolled and unregulated cell proliferation. Precisely what causes cells to become malignant and proliferate in an uncontrolled and unregulated manner has been the focus of intense research in recent decades. This research has led to the identification of many molecular targets associated with key metabolic pathways known to be associated with malignancy.
[0005] Heat shock factor 1 (HSF1) is one such target molecule. HSF1 is a master regulator of the heat shock response, in which multiple genes are induced in respo...